Report
Thomas Vranken

argenx FIRST LOOK: FY24 results highlight transition to sustainable profitability

argenx reported its FY24 financial results, underscoring Vyvgart's sustained commercial momentum and the company's pivot toward sustainable profitability. Despite increasing competition, we see no signs of stopping. For 2025, we mainly look forward to Vyvgart's ramp-up in CIDP, its PFS approval (PDUFA April 10), a PoC readout in LN and ARGX-119's first clinical results in CMS. We maintain our € 670 TP and Accumulate rating.
Underlying
ArGEN-X SE

Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Thomas Vranken

Other Reports on these Companies
Other Reports from KBC Securities
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch